ArticleJournal of public health research2026
Direct medical costs for drug-resistant tuberculosis inpatients at the national lung hospital, Vietnam: A one-year study.
Article in Journal of public health research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Abstract: Drug-resistant tuberculosis remains a major global public health challenge due to its complex treatment regimens and prolonged treatment duration. Drug-resistant tuberculosis treatment requires more expensive second-line medications, intensive monitoring, and longer hospitalization, resulting in substantially higher healthcare costs. Vietnam is one of 30 countries with a high burden of tuberculosis and drug-resistant tuberculosis. Objective: This study aims to investigate direct medical costs and associated factors of the costs in drug-resistant tuberculosis inpatients. Methods: A retrospective study was conducted at the National Lung Hospital. Medical and financial data of 629 inpatients with drug-resistant tuberculosis inpatients who discharged from the hospital from January 1st to December 31st, 2024, were collected. Results: The median of total inpatient treatment cost for a hospital stay was $707.2, and costs of drugs and intravenous fluids accounted for the highest proportion (38%) of total costs. Length of stays, number of comorbidities, and age were independent predictors of increased the direct medical costs of drug-resistant tuberculosis inpatients. Conclusions: Treatment costs for DR-TB in Vietnam remain high, highlighting the need for targeted financial support for vulnerable patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.